A multicenter prospective evaluation of the benefits of Dexcom ONE plus in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study
Por:
Chico, A, Aguilera-Hurtado, E, Albareda, M, Moreno-Fernández, J, Beato-Vibora, P, Fernández-Rubio, E, Cuesta, M, Bartual, A, Ampudia-Blasco, FJ, Bandrés, O, Ares, J, Rivero, MT and Picón-César, MJ
Publicada:
11 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
Aims Continuous glucose monitoring (CGM) has demonstrated to improve glucose control in people with type 2 diabetes (T2D) especially in those on insulin therapy. Dexcom ONE + is a CGM system with some particular features, however, there is no clinical study conducted with this device. The aim was to determine whether Dexcom ONE + can improve glucose control and patient-reported outcomes in insulin-treated T2D subjects. Methods Prospective, multicenter study including T2D on multiple insulin injections (MDI) or basal insulin (BI), with-out CGM experience and HbA1c > 7% (53 mmol/l). They used blinded Dexcom ONE + for 10 days and in open mode for 12 weeks. HbA1c, CGM-metrics, quality of life, fear and awareness of hypoglycemia were obtained baseline and at 12-weeks, and treatment satisfaction at 12 weeks. Results 159 subjects completed the study (MDI 75, BI 84). HbA1c decreased in MDI group from 8.18 +/- 1.3% (65.9 +/- 3.3 mmol/mol) to 7.34 +/- 0.8% (56.7 +/- 2.1 mmol/mol) and in BI group from 8.13 +/- 1.3% (65 +/- 3.3 mmol/mol) to 7.32 +/- 0.7% (56.5 +/- 1.9 mmol/mol) (p < 0.01). TIR increased in MDI group from 52.1 +/- 25% to 60.7 +/- 22% (p = 0.011) and in BI group from 58.8 +/- 22% to 65.8 +/- 19% (p = 0.0015). High degree of satisfaction and improvement in quality of life were observed in both groups and lower fear of hypoglycemia in BI group. Conclusions In this first clinical study, Dexcom ONE + enhanced glycemic control and improve patient-reported outcomes with high satisfaction.
Filiaciones:
Chico, A:
Hosp Santa Creu & St Pau Barcelona, Endocrinol & Nutr Dept, C San Quintin 167, Barcelona 08025, Spain
Inst Recerca St Pau IR St PAU, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Inst Salud Carlos III, CIBER BBN, Madrid, Spain
:
Germans Trias & Pujol Univ Hosp, Endocrinol & Nutr Dept, Badalona, Spain
Albareda, M:
Complex Hosp Univ Moises Broggi, Endocrinol & Nutr Dept, Barcelona, Spain
Moreno-Fernández, J:
Ciudad Real Gen Univ Hosp, Endocrinol & Nutr Dept, Ciudad Real, Spain
Castilla La Mancha Univ, Ciudad Real, Spain
Castilla La Mancha Inst Hlth Res, Toledo, Spain
Beato-Vibora, P:
Badajoz Univ Hosp, Endocrinol & Nutr Dept, Badajoz, Spain
Fernández-Rubio, E:
Cruces Univ Hosp, Endocrinol & Nutr Dept, Bilbao, Spain
Cuesta, M:
Hosp Clin Univ San Carlos, Endocrinol & Nutr Dept, Madrid, Spain
Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain
Univ Complutense Madrid, Madrid, Spain
Inst Salud Carlos III, CIBERDEM, Madrid, Spain
Bartual, A:
Clin Univ Hosp Valencia, Endocrinol & Nutr Dept, Valencia, Spain
Ampudia-Blasco, FJ:
Clin Univ Hosp Valencia, Endocrinol & Nutr Dept, Valencia, Spain
Univ Valencia, Valencia, Spain
Bandrés, O:
Lozano Blesa Univ Hosp, Endocrinol & Nutr Dept, Zaragoza, Spain
Ares, J:
Cent Univ Hosp Asturias, Endocrinol & Nutr Dept, Oviedo, Spain
Inst Invest Sanitaria Principado Asturias, Oviedo, Spain
Univ Oviedo, Oviedo, Spain
Rivero, MT:
Complejo Hosp Univ Ourense, Endocrinol & Nutr Dept, Ourense, Spain
Picón-César, MJ:
Virgen La Victoria Univ Hosp, Endocrinol & Nutr Dept, Malaga, Spain
Inst Invest Biomed Malaga, Malaga, Spain
Plataforma Nanomed IBIMA Plataforma BIONAND, Malaga, Spain
Inst Salud Carlos III, CIBERObn, Madrid, Spain
Green Submitted
|